JP2007517050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517050A5 JP2007517050A5 JP2006547486A JP2006547486A JP2007517050A5 JP 2007517050 A5 JP2007517050 A5 JP 2007517050A5 JP 2006547486 A JP2006547486 A JP 2006547486A JP 2006547486 A JP2006547486 A JP 2006547486A JP 2007517050 A5 JP2007517050 A5 JP 2007517050A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- atomoxetine
- form according
- oral dosage
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 84
- LUCXVPAZUDVVBT-UNTBIKODSA-N atomoxetine hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C LUCXVPAZUDVVBT-UNTBIKODSA-N 0.000 claims 81
- 229960002430 atomoxetine Drugs 0.000 claims 64
- 239000006186 oral dosage form Substances 0.000 claims 60
- 230000036470 plasma concentration Effects 0.000 claims 41
- 239000013543 active substance Substances 0.000 claims 35
- 239000008199 coating composition Substances 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 26
- 239000011248 coating agent Substances 0.000 claims 23
- 238000000576 coating method Methods 0.000 claims 23
- 229920000642 polymer Polymers 0.000 claims 18
- 239000008297 liquid dosage form Substances 0.000 claims 16
- 239000007909 solid dosage form Substances 0.000 claims 15
- 229960002828 atomoxetine hydrochloride Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 claims 13
- 239000011159 matrix material Substances 0.000 claims 10
- 101100083446 Danio rerio plekhh1 gene Proteins 0.000 claims 9
- 229920001577 copolymer Polymers 0.000 claims 9
- 239000000463 material Substances 0.000 claims 9
- 229920002959 polymer blend Polymers 0.000 claims 8
- 229920001477 hydrophilic polymer Polymers 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 239000001856 Ethyl cellulose Substances 0.000 claims 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 5
- 229920001249 ethyl cellulose Polymers 0.000 claims 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 4
- 239000004203 carnauba wax Substances 0.000 claims 4
- 235000013869 carnauba wax Nutrition 0.000 claims 4
- 229940082483 carnauba wax Drugs 0.000 claims 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000002609 medium Substances 0.000 claims 4
- 239000004014 plasticizer Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 229940012488 strattera Drugs 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000001993 wax Substances 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 2
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000006057 Non-nutritive feed additive Substances 0.000 claims 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- -1 aliphatic alcohols Chemical class 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 2
- 229960000623 carbamazepine Drugs 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 229960002896 clonidine Drugs 0.000 claims 2
- 229960003914 desipramine Drugs 0.000 claims 2
- 229960000632 dexamfetamine Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 239000001087 glyceryl triacetate Substances 0.000 claims 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 2
- 229960002048 guanfacine Drugs 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 2
- 229960004801 imipramine Drugs 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000006194 liquid suspension Substances 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 229960001078 lithium Drugs 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 229960001158 nortriptyline Drugs 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims 2
- 229960000761 pemoline Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000193 polymethacrylate Polymers 0.000 claims 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 239000006068 taste-masking agent Substances 0.000 claims 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims 2
- 229960002622 triacetin Drugs 0.000 claims 2
- 229940102566 valproate Drugs 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical group CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 239000000440 bentonite Substances 0.000 claims 1
- 229910000278 bentonite Inorganic materials 0.000 claims 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 230000001055 chewing effect Effects 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229940043348 myristyl alcohol Drugs 0.000 claims 1
- MHNFDKSVERZGHK-UHFFFAOYSA-N n,n-diethylethanamine;2-methylprop-2-enoic acid Chemical compound CC(=C)C([O-])=O.CC[NH+](CC)CC MHNFDKSVERZGHK-UHFFFAOYSA-N 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920006254 polymer film Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 229940098780 tribehenin Drugs 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53351703P | 2003-12-31 | 2003-12-31 | |
| PCT/US2004/043678 WO2005065673A1 (en) | 2003-12-31 | 2004-12-23 | Atomoxetine formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517050A JP2007517050A (ja) | 2007-06-28 |
| JP2007517050A5 true JP2007517050A5 (https=) | 2008-01-17 |
Family
ID=34748912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547486A Pending JP2007517050A (ja) | 2003-12-31 | 2004-12-23 | アトモキセチン製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050152974A1 (https=) |
| EP (1) | EP1715856B1 (https=) |
| JP (1) | JP2007517050A (https=) |
| AU (1) | AU2004312059A1 (https=) |
| CA (1) | CA2552064A1 (https=) |
| ES (1) | ES2390879T3 (https=) |
| WO (1) | WO2005065673A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
| US20080031932A1 (en) * | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
| US20080153808A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain |
| JP2012513475A (ja) * | 2008-12-23 | 2012-06-14 | レヴァイン，ジョシュア・ディー | 薬物療法学養生法において感覚的な条件付け手がかり（ｓｅｎｓｏｒｙｃｏｎｄｉｔｉｏｎｉｎｇｃｕｅｓ）を付け加える方法 |
| EP2213278A1 (de) * | 2009-01-28 | 2010-08-04 | Labtec GmbH | Pharmazeutische Zubereitung mit verbesserter Stabilität des Wirkstoffs |
| WO2010151745A1 (en) * | 2009-06-25 | 2010-12-29 | Elite Laboratories, Inc. | Oral dosage forms |
| CN102958515A (zh) | 2009-12-02 | 2013-03-06 | 阿普塔利斯制药有限公司 | 非索非那定微胶囊及含有非索非那定微胶囊的组合物 |
| US20110212171A1 (en) * | 2010-01-08 | 2011-09-01 | Eurand, Inc. | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| ES2689520T3 (es) | 2010-04-23 | 2018-11-14 | Kempharm, Inc. | Formulación terapéutica para reducir los efectos secundarios de fármacos |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| WO2013059676A1 (en) | 2011-10-21 | 2013-04-25 | Subhash Desai | Compositions for reduction of side effects |
| US10556011B2 (en) | 2011-12-02 | 2020-02-11 | Joshua D. Levine | Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen |
| US20160022591A1 (en) * | 2013-03-15 | 2016-01-28 | Mylan Inc. | Extended release pharmaceutical solid dosage formulations |
| PT2838510T (pt) | 2013-11-08 | 2016-11-23 | Lilly Co Eli | Solução de atomoxetina |
| GR1008531B (el) * | 2014-03-21 | 2015-07-13 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε., | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη |
| GB201420311D0 (en) | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Pharmaceutical processing |
| GB201420300D0 (en) * | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Tablet |
| GB201420306D0 (en) | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Compositions |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| EP3069715A1 (en) * | 2015-03-20 | 2016-09-21 | Salmon Pharma GmbH | Immediate release dosage forms of Atomoxetine |
| GR1008819B (el) | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου |
| ES2967863T3 (es) | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| US20170348288A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| JP2018020999A (ja) * | 2016-08-05 | 2018-02-08 | 高田製薬株式会社 | アトモキセチン錠剤およびアトモキセチン錠剤の製造方法 |
| CA3075292A1 (en) * | 2017-10-20 | 2019-04-25 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
| WO2020264092A1 (en) * | 2019-06-26 | 2020-12-30 | Celista Pharmaceuticals Llc | Atomoxetine hydrochloride extended release compositions and methods of use |
| JP7090847B2 (ja) * | 2020-12-01 | 2022-06-27 | 高田製薬株式会社 | アトモキセチン錠剤およびアトモキセチン錠剤の製造方法 |
| EP4304565A1 (en) * | 2021-03-09 | 2024-01-17 | Tulex Pharmaceuticals, Inc. | Extended-release compositions comprising atomoxetine |
| AU2023365355A1 (en) * | 2022-10-19 | 2025-05-29 | Vitakey Inc. | Formulated food products |
| WO2025067690A1 (en) * | 2023-09-29 | 2025-04-03 | Roquette Freres | Use of a stearic acid salt for improving the surface of sugar-coated solid forms |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US4018895A (en) * | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
| US4584404A (en) * | 1974-01-10 | 1986-04-22 | Eli Lilly And Company | Substituted phenoxyphenylproply dimethylamines |
| US4194009A (en) * | 1974-01-10 | 1980-03-18 | Eli Lilly And Company | Aryloxyphenylpropylamines for obtaining a psychotropic effect |
| US4777291A (en) * | 1985-02-27 | 1988-10-11 | Eli Lilly And Company | Racemization process |
| US4797286A (en) * | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
| US4847092A (en) * | 1985-11-12 | 1989-07-11 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
| IE64726B1 (en) * | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
| US4868344A (en) * | 1988-03-30 | 1989-09-19 | Aldrich-Boranes, Inc. | Novel process of producing phenyl or substituted phenylalkylamine pharmaceutical agents and novel chiral intermediates of high enantiomeric purity useful therein |
| US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
| US5356812A (en) * | 1990-08-10 | 1994-10-18 | Daicel Chemical Industries, Ltd. | Processes for production of optically active 3-phenyl-1,3-propanediol by asymmetric assimilation |
| DK0492497T3 (da) * | 1990-12-24 | 1997-01-06 | Hoechst Ag | Fremgangsmåde til acylering af alkoholer med en immobiliseret pseudomonas-lipase |
| CA2061665C (en) * | 1991-02-25 | 2002-04-16 | Mark Mortensen Foreman | Treatment of lower urinary tract disorders |
| EP0518263A1 (en) * | 1991-06-10 | 1992-12-16 | Hoechst-Roussel Pharmaceuticals Incorporated | Micropellets and a process for their manufacture |
| US5328697A (en) * | 1992-02-10 | 1994-07-12 | Mallinckrodt Veterinary, Inc. | Compositions and processes for the sustained release of drugs |
| US5395983A (en) * | 1992-07-23 | 1995-03-07 | Chisso Corporation | Process for producing 1-phenyl-1,3-propanediols having high optical purtiy |
| US6162949A (en) * | 1994-12-16 | 2000-12-19 | Uop Llc | Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers |
| US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
| CA2277220A1 (en) * | 1997-01-10 | 1998-07-16 | Abbott Laboratories | Tablet for the controlled release of active agents |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| JP4344405B2 (ja) * | 1997-08-26 | 2009-10-14 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | ピペリジノアルカノール−鬱血除去剤の組合せ用医薬組成物 |
| UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
| UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| EP1017372A4 (en) * | 1997-10-03 | 2006-05-24 | Smithkline Beecham Corp | SOLID GALENIC FORMS WITH CONTROLLED LITHIUM CARBONATE RELEASE |
| ZA989251B (en) * | 1997-10-17 | 2000-04-10 | Lilly Co Eli | Potentiation of pharmaceuticals. |
| US6245782B1 (en) * | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| ITMI991316A1 (it) * | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
| JP2005501070A (ja) * | 2001-08-08 | 2005-01-13 | イーライ・リリー・アンド・カンパニー | 神経障害を処置するための組み合わせ療法 |
| JP4848101B2 (ja) * | 2001-08-17 | 2011-12-28 | 株式会社フジモト・コーポレーション | 徐放性マイクロペレット |
| US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20050096349A1 (en) * | 2003-11-03 | 2005-05-05 | University Of Florida | Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning |
-
2004
- 2004-12-23 AU AU2004312059A patent/AU2004312059A1/en not_active Abandoned
- 2004-12-23 JP JP2006547486A patent/JP2007517050A/ja active Pending
- 2004-12-23 CA CA002552064A patent/CA2552064A1/en not_active Abandoned
- 2004-12-23 EP EP04815693A patent/EP1715856B1/en not_active Expired - Lifetime
- 2004-12-23 ES ES04815693T patent/ES2390879T3/es not_active Expired - Lifetime
- 2004-12-23 US US11/022,338 patent/US20050152974A1/en not_active Abandoned
- 2004-12-23 WO PCT/US2004/043678 patent/WO2005065673A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517050A5 (https=) | ||
| US5807579A (en) | Pseudoephedrine combination pharmaceutical compositions | |
| JP5607670B2 (ja) | 時限拍動性薬物送達システム | |
| HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
| US20210220281A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| TW200524643A (en) | Pantoprazole multiparticulate formulations | |
| US20040076669A1 (en) | Tramadol-based medicament | |
| JP3017040B2 (ja) | トリメタジジンの経口投与用持続的放出型薬剤組成物 | |
| US20250295596A1 (en) | Multiparticulate oral dosage form providing prolonged release of tapentadol | |
| AU782059B2 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
| CN1341014A (zh) | 含氯雷他定和伪麻黄碱的药物胶囊组合物 | |
| WO2007112574A1 (en) | Extended release composition of venlafaxine | |
| US20110244050A1 (en) | Pulsed-release sildenafil composition and method for preparing said composition | |
| US11622938B2 (en) | Oral pharmaceutical compositions of nicotinamide | |
| US20030228359A1 (en) | Pharmaceutical formulations containing epinastine, belladonna, and pseudoephedrine | |
| US20090028935A1 (en) | Carvedilol forms, compositions, and methods of preparation thereof | |
| US20210290557A1 (en) | Multi-particulate pharmaceutical composition, immediate release pellets, sustained release pellets, enteric release pellets and use thereof | |
| CN101829070A (zh) | 一种克拉霉素缓释分散片及其制备方法 | |
| US20220016058A1 (en) | Pharmaceutical composition containing tamsulosin hydrochloride with excellent acid resistance and preparation method therefor | |
| US7465462B1 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
| JP2020523290A (ja) | 遅延持続放出医薬組成物 | |
| EP2736496B1 (en) | Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof | |
| MX2014008975A (es) | Composicion de nitazoxanida mejorada y proceso para prepararla. | |
| TW201813643A (zh) | 杜洛希酊腸衣包覆醫藥組成物及其製造方法 | |
| TR2023000985A2 (tr) | Kontrollü salim sağlayan propi̇veri̇n formülasyonu |